Quick Answer
Biodexa Pharmaceuticals Plc reported R&D Expense of $3.96 million for fiscal year 2025.
Biodexa Pharmaceuticals Plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.96M | -27.1% |
| 2024 | $5.44M | +33.7% |
| 2023 | $4.07M | -20.4% |
| 2022 | $5.11M | +9.8% |
| 2021 | $4.65M | -23.3% |
| 2020 | $6.07M | -22.6% |
| 2019 | $7.84M | -16.2% |
| 2018 | $9.36M | +12.4% |
| 2017 | $8.33M | +7.7% |
| 2016 | $7.73M | -11.3% |
| 2015 | $8.71M | — |
- Biodexa Pharmaceuticals Plc showed a decrease of -27.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Biodexa Pharmaceuticals Plc’s r&d expense has declined by 54.5% (from $8.71 million to $3.96 million).
- The most recent figure is from Biodexa Pharmaceuticals Plc’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: